A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia
2010 ◽
Vol 106
(5)
◽
pp. 674-680
◽
2006 ◽
Vol 13
(11)
◽
pp. 1405-1409
◽
2014 ◽
pp. 113-128
2018 ◽
Vol 37
(1)
◽
pp. 143-153
◽
2007 ◽
Vol 120
(5)
◽
pp. 370-374
◽